Most genome editing work in agriculture tinkers with a handful of genes at once—typically five, maybe fewer. Rainbow Crops, a Belgian startup spun out of one of Europe's premier plant biology labs, is trying something considerably more ambitious: editing 50 to 100 genes simultaneously.
It's a technical leap that requires equal parts machine learning and molecular finesse, and investors appear convinced the gamble is worth it. The Ghent-based company closed an oversubscribed €9.7 million seed round (roughly $11.3 million) in mid-June 2026, led by LIFFT, an Italian deep-tech venture firm, alongside its LIFTT EuroInvest vehicle—a joint venture with the European Investment Bank focused on life sciences and cleantech.
The financing drew a broad syndicate. Agri Investment Fund, PINC, and VIB, all returning backers, were joined by Corteva Catalyst and Maia Ventures. The round came on the heels of a $7 million commitment from the Bill & Melinda Gates Foundation last November, aimed at developing heat and drought tolerance in maize, rice, and sorghum for smallholder farmers across Africa and Asia.
Rainbow Crops, which formally launched in April 2025 out of the VIB–UGent Center for Plant Systems Biology, is building what it calls a Trait Foundry platform—a system that stitches together AI-driven target prediction, multiplex genome editing, precision breeding, and automated phenotyping. CEO and co-founder Giacomo Bastianelli describes the approach as a departure from the field's incremental tendencies. "Not five genes at a time, but 50 to 100," he said, referencing vector design strategies the company uses to manage such large edit sets without overwhelming the biological machinery.
The platform can screen up to 16,000 plants per cycle, drawing on VIB's infrastructure. Phenotypic and omics data feed back into machine learning models, creating a loop that's supposed to accelerate trait discovery. Whether it works at commercial scale remains an open question. The company has run greenhouse trials and recently launched a small field pilot in corn focused on biomass and yield, though results were still under analysis as of June.
Rainbow Crops plans to license its trait outputs to seed and breeding companies, collecting royalties on commercialized varieties. The model also includes upfront R&D fees and milestone payments to smooth cash flow before royalty income materializes. Bastianelli hinted at an impending collaboration announcement with a corn seed company but offered no details or names.
The startup's scientific lineage runs through VIB–UGent research programs led by Dirk Inzé and Prof. Hilde Nelissen, the company's scientific founder and advisor. Nelissen specializes in maize growth dynamics and complex trait engineering—work that informed the multiplex editing strategy Rainbow Crops now aims to commercialize.
The fresh capital will go toward platform development, deployment in key crops, and hiring across scientific and technical roles. The company currently employs around 15 people, though that figure will likely grow as partnerships come online.
The funding arrives at a curious regulatory moment for Europe. The EU Council adopted New Genomic Techniques (NGT) rules in April 2026, potentially creating a faster approval path for certain genome-edited plants. But multiplex strategies involving dozens of simultaneous edits could face additional scrutiny under the framework's two-tier system. How regulators will treat Rainbow Crops' more aggressive editing approach remains unclear.
The deal also underscores sustained investor interest in AI-assisted crop engineering. Tropic Biosciences closed a $105 million Series C in March. Resurrect Bio pulled in around $10 million in a Series A backed by Corteva earlier this year. The appetite for climate-resilient agriculture tech shows no sign of cooling—perhaps appropriately, given the world it's trying to solve for.
